Merkel cell carcinoma (Cancer)
Information
- Disease name
- Merkel cell carcinoma
- Disease ID
- DOID:3965
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03228667 | Active, not recruiting | Phase 2 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | December 11, 2018 | December 2024 |
| NCT02196961 | Active, not recruiting | Phase 2 | Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation | June 2014 | August 31, 2024 |
| NCT04272034 | Active, not recruiting | Phase 1 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | March 26, 2021 | June 20, 2026 |
| NCT04234113 | Active, not recruiting | Phase 1 | Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors | June 13, 2019 | November 2024 |
| NCT04160065 | Active, not recruiting | Phase 1 | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers | March 3, 2020 | March 31, 2024 |
| NCT04116320 | Active, not recruiting | Phase 1 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors | November 21, 2019 | February 2024 |
| NCT03071406 | Active, not recruiting | Phase 2 | Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | March 14, 2017 | July 2024 |
| NCT02978625 | Active, not recruiting | Phase 2 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | September 27, 2017 | September 1, 2025 |
| NCT04242199 | Active, not recruiting | Phase 1 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | September 4, 2020 | October 31, 2025 |
| NCT04853602 | Available | IFx-Hu2.0 Expanded Access Program | |||
| NCT03798639 | Completed | Phase 1 | Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer | January 7, 2019 | December 2, 2022 |
| NCT01526486 | Completed | N/A | Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer | June 2009 | February 2013 |
| NCT02035657 | Completed | Phase 1 | A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma | January 2014 | March 2018 |
| NCT00346385 | Completed | Phase 1 | BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors | March 2002 | October 2011 |
| NCT02514824 | Completed | Phase 1/Phase 2 | MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma | October 2015 | June 2017 |
| NCT02643303 | Completed | Phase 1/Phase 2 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | December 28, 2016 | February 23, 2022 |
| NCT02819843 | Completed | Phase 2 | A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | June 21, 2016 | February 22, 2024 |
| NCT05422781 | Completed | Phase 1 | Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC) | June 13, 2022 | June 27, 2023 |
| NCT03783078 | Completed | Phase 3 | Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) | February 25, 2019 | February 15, 2024 |
| NCT01440816 | Completed | Phase 2 | IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer | January 3, 2012 | April 10, 2015 |
| NCT03841110 | Completed | Phase 1 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | February 15, 2019 | November 15, 2022 |
| NCT05253144 | Completed | N/A | Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC | March 19, 2016 | April 13, 2023 |
| NCT00540566 | Completed | Optical Biopsy of Human Skin in Conjunction With Laser Treatment | June 1999 | July 2008 | |
| NCT00765193 | Completed | N/A | The Impact of Total Body Skin Examination on Skin Cancer Detection | May 2008 | May 2009 |
| NCT04393753 | Completed | Phase 2 | Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 | October 13, 2020 | February 26, 2024 |
| NCT03458117 | Completed | Phase 1 | T-VEC in Non-melanoma Skin Cancer | April 19, 2018 | March 15, 2022 |
| NCT03538028 | Completed | Phase 1 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | June 18, 2018 | October 7, 2020 |
| NCT03545334 | Completed | N/A | Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study | September 1, 2017 | October 31, 2020 |
| NCT01013779 | Completed | Phase 2 | Merkel Positron Emission Tomography (PET) Protocol | December 2009 | June 2021 |
| NCT03629756 | Completed | Phase 1 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | July 24, 2018 | September 3, 2021 |
| NCT03652077 | Completed | Phase 1 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | September 24, 2018 | August 18, 2021 |
| NCT06039033 | Not yet recruiting | Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns | October 2024 | October 2026 | |
| NCT06448611 | Not yet recruiting | Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma | July 1, 2024 | June 1, 2027 | |
| NCT06086288 | Not yet recruiting | Phase 2 | Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC) | November 2023 | December 2027 |
| NCT05594290 | Recruiting | Phase 2 | Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery | December 7, 2022 | November 2026 |
| NCT02479698 | Recruiting | Phase 2 | Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus | July 23, 2015 | July 31, 2024 |
| NCT03210935 | Recruiting | French National Database of Rare Dermatological Cancers | November 24, 2015 | December 31, 2025 | |
| NCT03212404 | Recruiting | Phase 1 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | September 20, 2017 | December 2024 |
| NCT03583528 | Recruiting | DOTATOC PET/CT for Imaging NET Patients | July 11, 2018 | December 31, 2028 | |
| NCT03787602 | Recruiting | Phase 1/Phase 2 | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | March 19, 2019 | August 2025 |
| NCT03935893 | Recruiting | Phase 2 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | December 3, 2019 | June 30, 2037 |
| NCT04157985 | Recruiting | Phase 3 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | November 15, 2019 | October 2028 |
| NCT04977453 | Recruiting | Phase 1/Phase 2 | GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors | August 2, 2021 | October 2026 |
| NCT05076760 | Recruiting | Phase 1 | MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer | February 23, 2022 | November 2026 |
| NCT05078047 | Recruiting | Phase 3 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO | March 8, 2022 | March 7, 2025 |
| NCT05086692 | Recruiting | Phase 1/Phase 2 | A Beta-only IL-2 ImmunoTherapY Study | August 27, 2021 | December 30, 2026 |
| NCT05100095 | Recruiting | Phase 2 | Hypofractionated Radiation Therapy for Merkel Cell Carcinoma | December 14, 2021 | September 1, 2028 |
| NCT05120271 | Recruiting | Phase 1/Phase 2 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors | May 18, 2022 | December 2041 |
| NCT05329792 | Recruiting | Phase 2 | L19IL2/L19TNF in Skin Cancer Patients | March 9, 2023 | December 2024 |
| NCT05358938 | Recruiting | Early Phase 1 | Exercise to Boost Response to Checkpoint Blockade Immunotherapy | June 21, 2022 | September 2024 |
| NCT05429866 | Recruiting | Phase 2 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | September 1, 2022 | December 1, 2024 |
| NCT05496036 | Recruiting | Phase 2 | Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma | February 13, 2023 | September 30, 2026 |
| NCT05583708 | Recruiting | Phase 2 | Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer | August 3, 2023 | September 2026 |
| NCT05859074 | Recruiting | Phase 1 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | May 4, 2023 | May 4, 2028 |
| NCT06008977 | Recruiting | N/A | Exercise to Boost Response to Checkpoint Blockade Immunotherapy | December 2023 | May 2025 |
| NCT06021626 | Recruiting | Phase 1 | A Study of CRD3874-SI in People With Solid Tumors | August 25, 2023 | August 2029 |
| NCT06047379 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | November 1, 2023 | August 31, 2026 |
| NCT06056895 | Recruiting | Phase 2 | Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma | November 8, 2023 | December 31, 2029 |
| NCT06151236 | Recruiting | Phase 2 | Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma | March 11, 2024 | April 2034 |
| NCT06223659 | Recruiting | Phase 2 | EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers | December 19, 2023 | December 31, 2025 |
| NCT04260802 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | October 6, 2020 | September 30, 2026 |
| NCT04291885 | Recruiting | Phase 2 | Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma | October 26, 2020 | April 1, 2028 |
| NCT04349436 | Recruiting | Phase 1/Phase 2 | A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies | May 15, 2020 | January 2028 |
| NCT04616248 | Recruiting | Phase 1 | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | January 9, 2023 | January 9, 2026 |
| NCT04725331 | Recruiting | Phase 1/Phase 2 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | February 25, 2021 | April 30, 2025 |
| NCT04792073 | Recruiting | Phase 2 | Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma | March 8, 2021 | March 2025 |
| NCT04869137 | Recruiting | Phase 2 | Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma | May 28, 2021 | February 2025 |
| NCT04975152 | Recruiting | Phase 1 | Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma | October 22, 2021 | July 2026 |
| NCT04916002 | Suspended | Phase 2 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | November 30, 2021 | July 29, 2027 |
| NCT04187872 | Terminated | Phase 1 | LITT and Pembrolizumab in Recurrent Brain Metastasis | January 10, 2020 | December 1, 2023 |
| NCT03988647 | Terminated | Phase 2 | Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma | July 24, 2019 | January 20, 2021 |
| NCT03901573 | Terminated | Phase 1/Phase 2 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | December 26, 2019 | August 15, 2023 |
| NCT03853317 | Terminated | Phase 2 | QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy | February 24, 2020 | October 1, 2021 |
| NCT02036476 | Terminated | Phase 2 | Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | February 2014 | July 2016 |
| NCT04106167 | Terminated | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | June 11, 2019 | August 11, 2023 | |
| NCT03435640 | Terminated | Phase 1/Phase 2 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies | March 15, 2018 | May 9, 2022 |
| NCT04590781 | Terminated | Phase 1/Phase 2 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | May 10, 2021 | March 24, 2022 |
| NCT04596033 | Terminated | Phase 1 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | November 11, 2020 | June 27, 2022 |
| NCT02054884 | Terminated | Phase 2 | F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma | October 25, 2013 | December 15, 2017 |
| NCT03370861 | Unknown status | How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes | November 8, 2017 | December 31, 2022 | |
| NCT04705389 | Unknown status | N/A | SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines | September 2021 | September 2023 |
| NCT01913691 | Withdrawn | Phase 2 | Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma | July 9, 2013 | February 3, 2014 |
| NCT02831179 | Withdrawn | Phase 1 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | December 2017 | February 2020 |
| NCT04874831 | Withdrawn | Phase 2 | Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1) | November 1, 2021 | September 2025 |
| NCT03167164 | Withdrawn | Phase 1/Phase 2 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy | December 2017 | March 2019 |
| NCT00003514 | Withdrawn | Phase 2 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy |
- Disase is a (Disease Ontology)
- DOID:3451
- Cross Reference ID (Disease Ontology)
- GARD:9266
- Cross Reference ID (Disease Ontology)
- ICDO:8247/3
- Cross Reference ID (Disease Ontology)
- NCI:C4068
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:29792007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0302182
- Exact Synonym (Disease Ontology)
- Trabecular adenocarcinoma
- Exact Synonym (Disease Ontology)
- trabecular carcinoma